Market Research Logo

Smallpox - Pipeline Review, H2 2015

Smallpox - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Smallpox - Pipeline Review, H2 2015’, provides an overview of the Smallpox’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Smallpox
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Smallpox and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Smallpox products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Smallpox pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Smallpox
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Smallpox Overview
Therapeutics Development
Pipeline Products for Smallpox - Overview
Pipeline Products for Smallpox - Comparative Analysis
Smallpox - Therapeutics under Development by Companies
Smallpox - Therapeutics under Investigation by Universities/Institutes
Smallpox - Pipeline Products Glance
Late Stage Products
Early Stage Products
Unknown Stage Products
Smallpox - Products under Development by Companies
Smallpox - Products under Investigation by Universities/Institutes
Smallpox - Companies Involved in Therapeutics Development
Bavarian Nordic A/S
CEL-SCI Corporation
Chimerix, Inc.
EpiVax, Inc.
Nanotherapeutics, Inc.
Oncovir, Inc.
SIGA Technologies, Inc.
Symphogen A/S
TapImmune Inc.
Tonix Pharmaceuticals Holding Corp.
Smallpox - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
24a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brincidofovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cidofovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imatinib mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Infectious Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PL-801 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Poly-ICLC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
small pox vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
smallpox vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
smallpox vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sym-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tecovirimat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TPIV-300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VIR-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Smallpox - Recent Pipeline Updates
Smallpox - Dormant Projects
Smallpox - Discontinued Products
Smallpox - Product Development Milestones
Featured News & Press Releases
Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million
May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine
Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery
Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million
Dec 23, 2014: Chimerix Provides Recap of 2014 Events
Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine
Sep 04, 2014: Bavarian Nordic Announces Exercise Of Contract Option By The U.S. Government For Continued Supply Of Imvamune Smallpox Vaccine
Sep 02, 2014: Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox
Aug 26, 2014: Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE Smallpox Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Smallpox, H2 2015
Number of Products under Development for Smallpox - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Smallpox - Pipeline by Bavarian Nordic A/S, H2 2015
Smallpox - Pipeline by CEL-SCI Corporation, H2 2015
Smallpox - Pipeline by Chimerix, Inc., H2 2015
Smallpox - Pipeline by EpiVax, Inc., H2 2015
Smallpox - Pipeline by Nanotherapeutics, Inc., H2 2015
Smallpox - Pipeline by Oncovir, Inc., H2 2015
Smallpox - Pipeline by SIGA Technologies, Inc., H2 2015
Smallpox - Pipeline by Symphogen A/S, H2 2015
Smallpox - Pipeline by TapImmune Inc., H2 2015
Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Smallpox Therapeutics - Recent Pipeline Updates, H2 2015
Smallpox - Dormant Projects, H2 2015
Smallpox - Dormant Projects (Contd..1), H2 2015
Smallpox - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Smallpox, H2 2015
Number of Products under Development for Smallpox - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report